Replies to post #1171 on Israel-Medical-Healthcare

[genisi]

Does the lack of a complete dose response cause you to be more cautious especially with your other point about placebo crossovers?

The drug is an A3 adenosine receptor agonist and sounds like the high dose induced desensitization of the receptor. I have no biological explanation to the too quick placebo response after crossover.

I didn't see them listed in the JP Morgan agenda

I know you cannot read Hebrew but you can see 'JP Morgan' in the 7th line in their PR here:

http://www.canfite.com/upload/2012-12-30%20Psoriasis%20additional%20analysis%20%20-%20Hebrew.pdf

I suppose they will set meetings with potential investors there, so nothing you can listen to. Come over if you wanna have a sunny week plus a meeting with the company :-)